

Clinical Pathway Board Meeting 29th June 2017

Paper 1 – Minutes of the Board meeting held on 2nd May 2017

Presented by Satish Maddineni

Actions for the Board

1. The board to approve the record

Urology Pathway Board Meeting

Minutes of the meeting held on

May 2nd 2017

Members in attendance

Satish Maddineni (Chair)	Pathway Director	Jeremy Oates	Consultant Surgeon
Mike Thorpe	User representative	Jane Booker	Specialist CNS
Stephen Bromage	Consultant Surgeon	Mike Scott	Consultant Pathologist
Tony Elliot	Consultant Oncologist	Jacob Cherian	Consultant Surgeon
Helen Johnson	Specialist CNS	Tom Waddell	Consultant Oncologist
Tom Waddell	Consultant Oncologist	Kieran O'Flynn	Consultant Surgeon
Maryna Lewinski	Consultant Radiologist	Jacob Cherian	Consultant Surgeon

In attendance

James Leighton	GM Cancer	Sarah Darley	Respect 21 project
----------------	-----------	--------------	--------------------

1. Welcome and introductions

SM welcomed all to the meeting and noted the apologies received.

2. Minutes of the last meeting

These were accepted as a true record and there were no matters arising.

3. Cancer Vanguard Project Updates:**(i) Stratified Self-Management**

Discussion summary	HJ provided the board with an update on her work and talked the Board through the proposed pathways for surgical and Radiotherapy follow-ups. The Board had a wide ranging discussion on the proposal.
Conclusion	The board noted the presentation and approved the proposed pathways
Actions & responsibility	The Board asked HJ to confirm the pathways with the Vanguard team and agree the next steps with them.

(ii) Best timed Pathway project

Discussion summary	SM provided an update on the best timed prostate pathway. He explained the purpose of the project and the intention to create a national prostate pathway. He confirmed that work with London surgeons was about to commence
Conclusion	The Board noted this presentation.
Actions & responsibility	The Board asked that the project group continue with their work and provide regular reports to the Board.

4. The Greater Manchester Cancer plan

Discussion summary	JL provided an update on the GM Cancer plan and explained how the pathway board were expected to contribute to the delivery. He outlined to the Board the objectives for the next year and the board had an initial review. KoF outlined a potential "scorecard" for urology in GM based on CQC aspiration metrics and extracted from HES. He proposed that this is something that the Board could adopt.
Conclusion	The board noted this report.
Actions & responsibility	The Board agreed to support delivery of the plan and keep it under review. JL to review "Scorecard" proposal with GM Cancer.

5. Board Projects**(i) Janssen Project update**

Discussion summary	SM confirmed that work on this has not commenced due to difficulty accessing the data from Pennine Acute Trust. He advised that work was proceeding to overcome these difficulties.
Conclusion	The Board noted this report.
Actions & responsibility	There were no actions following discussion.

(iii) Active surveillance audit

Discussion summary	SB provided an update the Board on this audit and confirmed that data collection was under way. He was aware that some had not received the proforma and agreed to re0circulate.
--------------------	--

Conclusion	The Board noted this report.
Actions & responsibility	There were no actions following discussion.

6. Transformation update

Discussion summary	SM confirmed that there was a consensus on the future service provision but this was yet to be confirmed. He explained that once announced an implementation group would be put in place to begin the process of transition to the new service.
Conclusion	The Board noted this report.
Actions & responsibility	There were no actions following discussion.

7. User Involvement update

Discussion summary	ML confirmed that this was now her last attendance at the Board as she was taking up a role of pathway Manager with GM Cancer.
Conclusion	
Actions & responsibility	There were no actions following discussion.

8. Research update

Discussion summary	TE advised that this should be deferred to the next meeting.
Conclusion	
Actions & responsibility	TE to send out the portfolio of open trials to board members

9. Any other business

Discussion summary	There were no items of any other business
Conclusion	
Actions & responsibility	

Date and time of meeting **Tuesday 2nd May, 14.00 – 16.00hrs SRFT**

Date and time of meeting in 2017 **Wednesday 20th September**
Tuesday 14th November